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Background
Diabetes mellitus is a major public health concern with
devastating human, social and economic impact. It is
increasing globally, affecting more than 180 million people
worldwide. The objective of our study was to analyse the
overall volume of use of antidiabetics in Serbia compared
to Scandinavian countries (Sweden, Norway, Denmark),
chosen for their rational and conservative prescription
practice.
Methods
Data on consumption of antidiabetics (ATC group A10) in
2010 were extracted from the databases of the representa-
tive national authorities. Utilisation of these medicines was
measured through the defined daily dose (DDD) unit and
the results were expressed as DDD per 1000 inhabitants
per day (DID).
Results
In 2010, antidiabetics were used at a similar rate in Serbia
(47.3 DID) and Scandinavian countries (from 46.5 DID in
Sweden to 47.67 DID in Norway), but the share of use of
insulins (A10A) and oral antidiabetics (A10B) differed
among the observed countries. The proportion of insulin
in Serbia was 22.0% of all antidiabetics which is relatively
low in comparison with Scandinavian countries (from
36.2% in Denmark to 50.8% in Sweden). Utilisation of
long-acting insulins (A10AE) was much lower in Serbia
(1.3 DID) compared to Scandinavian countries (range:
2.6–4.6 DID). The share of oral antidiabetics use also dif-
fered among these countries. In Serbia, sulfonylureas
(A10BB), as a second-line treatment for type 2 diabetes,
were used predominantly (55.6%) compared to metformin
(44.1%). In Scandinavian countries, metformin, as pre-
ffered oral agent for type 2 diabetes and the only medicine
from the biguanide class (A10BA), was used at a higher
rate than in Serbia (from 51.2% in Denmark to 60.4% in
Sweden). New medicinal products with effect on the incre-
tin system (A10BH and A10BX) were also used at a higher
rate in Scandinavian countries (range: 0.5–2.5 DID) in
comparison to Serbia (0.002 DID).
Conclusions
This cross-national study has demonstrated large differ-
ences in the utilisation of various antidiabetics among
observed countries that may be attributed to considerable
variations in attitudes and habits, especially with regard to
the management of type 2 diabetes.
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